ImmunityBio is a clinical-stage immunotherapy company that develops next-generation therapies that aim to address the patient's immune system. The company's research and development efforts are focused on novel treatments for cancer, infectious diseases, and autoimmune diseases.

ImmunityBio, Inc.

ImmunityBio

NantKwest

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory.

Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases.

"At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman 

NantCapital

Oberland Capital

Patrick Soon-Shiong

Did you know? Firefighters are at a higher risk of developing cancer due to job-related carcinogen exposure. ImmunityBio is dedicated to advancing bladder cancer research, offering new treatments for these everyday heroes. Learn more at the American Cancer Society. https://lnkd.in/gtNi7wQG

ImmunityBio is looking forward to the American Urological Association (AUA) annual conference! We are excited to discuss our research, dive into insightful discussions, and connect with industry peers. Visit us in booth #1931. May 3-6, see you there! https://auanet.org/AUA2024 

On the National Mall stand more than 27,400 flags representing people under the age of 50 projected to be diagnosed with Colon Cancer in 2030, a cancer highly associated with Lynch Syndrome. Learn about our Lynch Syndrome cancer prevention efforts: https://lnkd.in/djjBtnwV

Friday, March 22nd, was Lynch Syndrome Awareness Day. ImmunityBio is dedicated to advancing research for early detection and treatment for this disease. Together, we can bring hope and change to the thousands of Americans with the Lynch syndrome genetic mutation. Learn more: https://lnkd.in/djjBtnwV

ImmunityBio is advancing research to end bladder cancer. Join us and the Bladder Cancer Advocacy Network (BCAN) to fight bladder cancer in the Walk to End Bladder Cancer. Every step you take makes a difference. Learn more about how you can participate: https://lnkd.in/gAsvzVT7

COM:IMMUNITYBIO

ImmunityBio

locale

market

industry

website

crunchbase

linkedin

founding date

peer of

investor of

competitor of

Metrics